



## Clinical trial results:

### An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects with Epidermolysis Bullosa Simplex (EBS)

#### Summary

EudraCT number	2017-003757-41
Trial protocol	GB AT NL DE FR
Global end of trial date	17 April 2020

#### Results information

Result version number	v1 (current)
This version publication date	17 October 2020
First version publication date	17 October 2020

#### Trial information

##### Trial identification

Sponsor protocol code	CCP-020-302
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03389308
WHO universal trial number (UTN)	-
Other trial identifiers	IND: 131 384

Notes:

##### Sponsors

Sponsor organisation name	Castle Creek Pharmaceuticals, LLC
Sponsor organisation address	233 Mt. Airy Road, Basking Ridge, United States, 07920
Public contact	Dr. Mary Spellman, Castle Creek Pharmaceuticals, LLC, +001 8622860400, mspellman@castlecreekpharma.com
Scientific contact	Dr. Mary Spellman, Castle Creek Pharmaceuticals, LLC, +001 8622860400, mspellman@castlecreekpharma.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 July 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 April 2020
Global end of trial reached?	Yes
Global end of trial date	17 April 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to evaluate the long-term safety and tolerability of Diacerein 1% Ointment in subjects with EBS that were previously enrolled in studies CCP-020-301 or CCP-020-101.

Protection of trial subjects:

The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), applicable regulatory requirements, and the Castle Creek Policy on Bioethics.

Background therapy:

-

Evidence for comparator:

-

Actual start date of recruitment	15 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Country: Number of subjects enrolled	United Kingdom: 7
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	France: 9
Country: Number of subjects enrolled	Germany: 2
Country: Number of subjects enrolled	Australia: 2
Country: Number of subjects enrolled	Israel: 5
Country: Number of subjects enrolled	United States: 22
Worldwide total number of subjects	51
EEA total number of subjects	22

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	33
Adolescents (12-17 years)	7
Adults (18-64 years)	11
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Subjects with EBS that were previously enrolled in studies CCP-020-301 or CCP-020-101 were recruited.

### Pre-assignment

Screening details:

At baseline, EBS subjects who participated in the CCP-020-301 double-blind safety and efficacy study or participated in the CCP-020-101 pharmacokinetic study (feeder studies) and who met all of the inclusion/exclusion criteria were eligible to enroll and complete up to 2 treatment cycles of diacerein 1% ointment in this study.

### Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Open Label
-----------	------------

Arm description:

Each treatment cycle consisted of 8 weeks on treatment (once-daily, at-home study drug applications) followed by 8 weeks off treatment (only Investigator-approved, bland, non-medicated emollient/moisturizer, routine cleansing products, and sunscreens were allowed off treatment), with a maximum of 2 treatment cycles allowed for up to 52 weeks.

Arm type	Experimental
Investigational medicinal product name	Diacerein
Investigational medicinal product code	CCP-020
Other name	
Pharmaceutical forms	Ointment
Routes of administration	Topical use

Dosage and administration details:

During the treatment period of each cycle, subjects/caregivers applied a thin layer of the assigned study drug, sufficient to cover the subject's EBS lesions and approximately  $\frac{3}{4}$  inch (2 cm) of surrounding uninvolved skin, and gently rubbed in the study drug. Subjects/caregivers applied the assigned study drug to all EBS lesions, including any new EBS lesions that developed (up to 30% BSA), once daily, every evening until the lesions resolved, for 8 weeks.

Number of subjects in period 1	Open Label
Started	51
Completed	39
Not completed	12
Consent withdrawn by subject	5
Adverse event, non-fatal	2
Sponsor request	2
Lost to follow-up	3



## Baseline characteristics

---

### Reporting groups

Reporting group title	Overall Trial
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall Trial	Total	
Number of subjects	51	51	
Age categorical			
Units: Subjects			
Children (2-11 years)	33	33	
Adolescents (12-17 years)	7	7	
Adults (18-64 years)	11	11	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	26	26	
Male	25	25	

## End points

### End points reporting groups

Reporting group title	Open Label
Reporting group description: Each treatment cycle consisted of 8 weeks on treatment (once-daily, at-home study drug applications) followed by 8 weeks off treatment (only Investigator-approved, bland, non-medicated emollient/moisturizer, routine cleansing products, and sunscreens were allowed off treatment), with a maximum of 2 treatment cycles allowed for up to 52 weeks.	

### Primary: Treatment-Emergent Adverse Events

End point title	Treatment-Emergent Adverse Events <sup>[1]</sup>
End point description: Number and percentage of participants with any treatment-emergent adverse event	
End point type	Primary
End point timeframe: Up to 52 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The primary objective of this safety study was to describe treatment-emergent adverse events.

<b>End point values</b>	Open Label			
Subject group type	Reporting group			
Number of subjects analysed	51			
Units: Count of Participants				
Treatment-Emergent Adverse Events	40			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 52 weeks

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	All study participants
-----------------------	------------------------

Reporting group description:

Safety population

Serious adverse events	All study participants		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 51 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	All study participants		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 51 (41.18%)		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	4 / 51 (7.84%)		
occurrences (all)	4		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	4 / 51 (7.84%)		
occurrences (all)	5		
Skin and subcutaneous tissue disorders			
Pruritus			



subjects affected / exposed occurrences (all)	4 / 51 (7.84%) 6		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	7 / 51 (13.73%)		
occurrences (all)	10		
Skin infection			
subjects affected / exposed	5 / 51 (9.80%)		
occurrences (all)	9		
Ear infection			
subjects affected / exposed	3 / 51 (5.88%)		
occurrences (all)	3		
Gastroenteritis viral			
subjects affected / exposed	3 / 51 (5.88%)		
occurrences (all)	3		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported